Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...

The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that ...

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

"Regeneron has invested many years of effort into its design and development of EYLEA® (aflibercept) Injection 2 mg. This work has resulted in numerous patents, reflecting our important research ...

intravitreal UBX1325 compared with Regeneron’s REGN Eylea (aflibercept) in diabetic macular edema (“DME”) patients. The primary efficacy endpoint of the phase IIb ASPIRE study is ...